Altrova Health Updates US Trading Symbol to ATVHF, Boosts O-Spray and NIRLAB Commercial Expansion Efforts

Altrova Health Adopts New OTCQB Symbol ATVHF to Align US Market Presence with Brand Identity

As of July 17, 2026, Altrova Health’s common shares began trading on the OTCQB under the new ticker "ATVHF," replacing the previous symbol "SSPLF." This rebranding aligns the company’s US trading identity with its Altrova Health brand. The change does not affect the company’s share structure, CUSIP number, or its ongoing listing on the Canadian Securities Exchange, where shares continue to trade under "ROVA."

This symbol update is primarily a branding alignment for US investors and does not impact Canadian trading. It aims to provide clearer consistency across North American trading platforms.

O-Spray Partnership Talks Poised to Accelerate Market Expansion

Altrova Health is progressing its O-Spray commercial rollout through active discussions with potential distribution and licensing partners. Management anticipates that finalizing these partnerships will significantly boost O-Spray’s market penetration across retail and healthcare practitioner channels. Further updates will be provided as agreements are secured.

The company’s approach favors an asset-light commercial model, leveraging third-party distributors to scale O-Spray sales without proportional increases in direct sales and marketing expenses. The timing and financial impact remain dependent on the conclusion of these agreements.

NIRLAB Device Strengthens Presence in Indigenous Community Safety Programs

Altrova Health recently sold an additional NIRLAB SA NIRLIGHT drug analysis device to a First Nation community, enhancing its footprint in Indigenous health and safety initiatives across Canada. This sale underscores ongoing demand for rapid, non-invasive drug detection technologies among community health and public safety stakeholders. The company has not disclosed total NIRLAB sales or the transaction value.

The NIRLIGHT device utilizes non-invasive technology for drug analysis, supporting harm reduction and community safety efforts. Targeting First Nation communities reflects a strategic focus on organizations prioritizing substance use and drug safety. Investors will likely monitor further NIRLAB sales and broader institutional adoption in Canada.

Drug Lab 118 Ltd. Rebrands Rapid Detection Strip Line with US and Canadian Expansion Focus

Through its wholly owned subsidiary Drug Lab 118 Ltd. ("Drug Lab US"), Altrova Health has rebranded and relaunched its rapid detection strip portfolio under the Altrova Health umbrella. The product lineup includes Drink Detective, Drug Detective, and Fentanyl Detective, each addressing critical public health needs. Drink Detective detects illicit substances and sedatives in beverages, Drug Detective identifies trace drug residues on surfaces, and Fentanyl Detective rapidly detects fentanyl and analogs in high-risk environments.

The new commercial strategy targets scaling distribution across educational institutions, hospitality venues, and municipal and public safety organizations in the US and Canada. Consolidating these products under Altrova Health aims to unify branding and enhance market presence. Financial targets and timelines for expansion have not been disclosed.

Jason Libenson Joins as Advisor Bringing Capital Markets and Asset Management Expertise

Altrova Health appointed Jason Libenson, President and COO of Castlewood Capital Corporation, as an advisor. Libenson has over a decade of financial services experience, including senior roles at asset managers and capital raising across mutual funds, hedge funds, and flow-through funds. He has served on multiple public company boards and holds a Bachelor of Commerce from Concordia University. He resides in Toronto.

His appointment aims to bolster Altrova Health’s capital markets and financing capabilities as the company advances its commercial initiatives. CEO Geoff Benic highlighted Libenson’s capital-raising expertise as a valuable asset for scaling the business.

Blaise Yerly Adds Over 30 Years of Public Company Governance and Market Experience

Also joining as an advisor, Blaise Yerly brings more than three decades of experience in Canadian public markets as an investor and director. Yerly served as director and Chairman of Aquiline Resources, acquired by Pan American Silver in 2009 for over $620 million in stock. He was a director of Treasury Metals (now NeXGold Mining) from 2008 to 2018 and Cypherpunk Holdings (now Sol Strategies Inc.) from 2017 to 2021.

Yerly has been Executive Chairman of Wacyba Ltd, a Swiss family holding company, since 2008, and previously built and sold a heavy equipment distribution business and asset-based finance company in sub-Saharan Africa. His extensive public market and international business experience is expected to provide strategic guidance as Altrova Health pursues growth. CEO Benic emphasized Yerly’s three decades of public company leadership as a key benefit.

CEO Highlights Strategic Importance of New Advisory Board Members for Growth

Altrova Health CEO Geoff Benic commented on the advisory appointments: "Jason and Blaise bring exactly the capital markets and public company experience we need as Altrova Health scales. Jason’s proven capital-raising across diverse investment vehicles, combined with Blaise’s three decades of public company leadership, offer valuable insights as we advance our commercial strategies for O-Spray, NIRLAB, and our rapid detection portfolio."

This underscores the company’s view that expanding its advisory board is critical to executing its multi-product growth strategy. The focus on O-Spray, NIRLAB, and rapid detection products highlights these as core areas for scaling. The addition of advisors with capital formation and governance expertise may indicate preparations for future financing or growth initiatives.

Clarification on Raf Souccar’s Advisory Role After Chairman Resignation

Altrova Health issued a correction regarding its July 2, 2026 press release, clarifying that Raf Souccar is not serving, nor has agreed to serve, in any advisory capacity following his resignation as Chairman. This correction rectifies prior communications and updates the company’s advisory structure. Investors should note this change when evaluating governance and advisory arrangements.

Altrova Health’s Diverse Product Portfolio and Commercial Strategy Overview

Altrova Health’s portfolio includes exclusive Canadian distribution rights for the NIRLAB SA NIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking detection products, the O-Spray line, and the rapid detection strip portfolio of Drug Lab 118 Ltd. This multi-product approach positions the company across detection, protection, and public health safety sectors. The company is advancing parallel commercial efforts: partnership development for O-Spray, direct sales for NIRLAB, and distribution expansion for rapid detection strips across North America.

The broad product suite and multiple commercial initiatives reflect a diversified revenue strategy. Investors will likely watch for announcements on O-Spray partnerships, NIRLAB adoption by institutions, and revenue growth from Drug Lab 118’s expanded distribution. The advisory board additions with capital markets and governance expertise suggest management is preparing for larger-scale operations and potential capital raising.